Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, septembre 26
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Oruka Therapeutics Inc
ORKA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$84.46
-1.03
-1.2%
À la clôture: Sep 25, 5:00 PM EST
$86.00
1.54
1.82%
Après les heures: 9:27 AM EST
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Dividendes
Comparer
Options
Rapport sur les stocks
Oruka Therapeutics Financials
Oruka Therapeutics (ORKA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Oruka Therapeutics Q2 EPS $(0.55) Misses $(0.51) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 19.57 percent decrease over losses of $(0.46) per share
Benzinga Newsdesk
PRO
Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent. This is a 20 percent decrease over losses of $(0.40) per share from
Benzinga Newsdesk
PRO
Oruka Therapeutics Q4 EPS $(0.45) Beats $(0.64) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.64) by 29.47 percent. This is a 8.16 percent increase over losses of $(0.49) per share from
Benzinga Newsdesk
PRO
Oruka Therapeutics Q3 EPS $(0.55) Beats $(0.59) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.59) by 6.14 percent. This is a 62.33 percent increase over losses of $(1.46) per share from
Benzinga Newsdesk
Stock Market Today: Dow Jones, Nasdaq, Futures Gain As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus (UPDATED)
Editor’s Note: The future prices of benchmark tracking ETFs were updated in the story. U.S. stock futures rose on Monday following Friday’s mixed moves. Futures of major benchmark indices were higher.
Rishabh Mishra
Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday
US stock futures up, focus on Constellation Brands, SkyWater Tech, Aehr Test Systems, Oruka Therapeutics and VCI Global earnings.
Avi Kapoor
Privacy Manager